C
Christopher John Rito
Researcher at Eli Lilly and Company
Publications - 38
Citations - 1259
Christopher John Rito is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Bisindolylmaleimide & Adrenergic. The author has an hindex of 17, co-authored 38 publications receiving 1235 citations.
Papers
More filters
Journal ArticleDOI
(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
Michael R. Jirousek,Gillig James Ronald,Cecile M. Gonzalez,William Francis Heath,John H. McDonald,David Andrew Neel,Christopher John Rito,Upinder Singh,Stramm Lawrence E,Anita Melikian-Badalian,Matthew Baevsky,Lawrence M. Ballas,Steven E. Hall,Leonard L. Winneroski,Margaret M. Faul +14 more
TL;DR: A novel series of 14-membered macrocycles containing a N-N'-bridged bisindolylmaleimide moiety and related ATP dependent kinase inhibition profiles is provided and compared to the profile for staurosporine, a nonselective PKC inhibitor.
Patent
Protein kinase c inhibitors
TL;DR: In this paper, a bis-indolemaleimide macrocycle derivatives of the formula were provided for inhibiting protein Kinase C in mammals. And the authors further provided the preparation, pharmaceutical formulations and the methods of use for inhibited protein kinase C.
Journal ArticleDOI
A Tailored Therapy for the Metabolic Syndrome: The Dual Peroxisome Proliferator-Activated Receptor-α/γ Agonist LY465608 Ameliorates Insulin Resistance and Diabetic Hyperglycemia While Improving Cardiovascular Risk Factors in Preclinical Models
Garret J. Etgen,Brian A. Oldham,William T. Johnson,Carol L. Broderick,Chahrzad R. Montrose,Joseph T. Brozinick,Elizabeth A. Misener,James S. Bean,William R. Bensch,Dawn A. Brooks,Anthony J. Shuker,Christopher John Rito,Mccarthy James R,Robert J. Ardecky,John S. Tyhonas,Sharon L. Dana,James M. Bilakovics,James R. Paterniti,Kathleen M. Ogilvie,Sha Liu,Raymond F. Kauffman +20 more
TL;DR: It is demonstrated that LY465608 beneficially impacts multiple facets of type 2 diabetes and associated cardiovascular risk, including those facets involved in the development of micro- and macrovascular complications, which are the major sources for morbidity and mortality in these patients.
Journal ArticleDOI
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
Dawn A. Brooks,Garret J. Etgen,Christopher John Rito,Anthony J. Shuker,Samuel J. Dominianni,Warshawsky Alan M,Robert J. Ardecky,James R. Paterniti,John S. Tyhonas,Donald S. Karanewsky,Raymond F. Kauffman,Carol L. Broderick,Brian A. Oldham,Chahzrad Montrose-Rafizadeh,Leonard L. Winneroski,Margaret M. Faul,Mccarthy James R +16 more
TL;DR: Propionic acid derivative 8, which was designed and synthesized based on putative pharmacophores of known PPARgamma- and PPAR alpha-selective compounds, exhibits potent dual PPARalpha/gamma agonist activity as demonstrated by in vitro binding and dose overlap in the newly introduced EOB mouse model for glucose lowering and lipid/cholesterol homeostasis.
Patent
Modulators of peroxisome proliferator activated receptors
Dawn A. Brooks,Christopher John Rito,Anthony J. Shuker,Samuel J. Dominianni,Warshawsky Alan M,Lynn S. Gossett,Donald P. Matthews,David A. Hay,Robert J. Ardecky,Pierre-Yves Michellys,John S. Tyhonas +10 more
TL;DR: In this article, a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.